Rituximab for the Treatment of Acute Refractory ITP
Kim SG, Whyte D, Pashankar FD. Rituximab for the Treatment of Acute Refractory ITP. Journal Of Pediatric Hematology/Oncology 2014, 36: e149-e151. PMID: 23669737, DOI: 10.1097/mph.0b013e318292f006.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAntibodies, Monoclonal, Murine-DerivedAntineoplastic AgentsChild, PreschoolDrug ResistanceFemaleHumansMalePurpura, Thrombocytopenic, IdiopathicRemission InductionRituximabSalvage TherapyTreatment OutcomeConceptsRefractory immune thrombocytopenic purpuraImmune thrombocytopenic purpuraFirst-line therapyTreatment of ITPAcute immune thrombocytopenic purpuraSecond-line therapySustained remissionIntravenous immunoglobulinIntravenous rituximabEffective regimenImmune globulinAcute settingThrombocytopenic purpuraCombined therapyRituximabMost childrenTherapyClear consensusTreatmentCorticosteroidsRemissionPurpuraRegimenPatientsImmunoglobulin